Shanghai UniXell Biotechnology (Unixell Biotech), a China-based biotechnology company focused on developing cell therapies for neurological disorders, has achieved a major regulatory milestone after receiving Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for its lead candidate UX-GIP001.

UX-GIP001 is an induced pluripotent stem cell (iPSC)-derived allogeneic cell therapy designed to treat focal Epilepsy. With this approval, the therapy became the first of its kind to enter clinical development in the United States, while also marking a significant step forward for China’s cell therapy innovations in neurological diseases.

Epilepsy is a chronic neurological condition affecting more than 70 million people worldwide, commonly seen in infants and elderly populations. It can result from brain injuries, trauma or surgical complications. While current treatment options such as surgical resection and neurostimulation provide relief for some patients, they are often associated with side effects and limited efficacy, particularly in drug-resistant cases.

Unixell’s UX-GIP001 aims to address these challenges by targeting the underlying cause of seizures—impaired GABAergic interneurons that lead to neural hyperexcitability. The therapy uses the company’s proprietary stem cell technology to generate inhibitory neural progenitor cells through directed differentiation. Once transplanted, these cells are designed to restore inhibitory neural circuits, thereby suppressing seizure activity.

Preclinical studies have demonstrated promising efficacy and safety outcomes in epileptic animal models, supporting the transition of UX-GIP001 into human clinical trials. The upcoming Phase I study will evaluate the safety, tolerability and preliminary efficacy of the therapy in patients with drug-resistant epilepsy.

The IND clearance strengthens Unixell Biotech’s broader pipeline focused on neurological diseases, including Parkinson's Disease and epilepsy—areas with significant unmet medical needs. The company is advancing both autologous and allogeneic cell therapy approaches to build a diversified and scalable treatment portfolio.

Founded in 2021, Unixell Biotech operates a 4,000-square-meter R&D and GMP manufacturing facility and has developed multiple advanced technology platforms, including stem cell differentiation, lineage tracing and gene editing. These capabilities support the development of high-purity, stable and clinically effective neural cell therapies.

With the advancement of UX-GIP001 into clinical trials, the company aims to accelerate the development of next-generation regenerative treatments and deliver safer, more effective therapeutic options for patients suffering from neurological disorders worldwide.